Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health is well positioned for future growth with its successful implementation of Performance Suite clients and additional contract wins. Their enhanced contract protections ensure stability and predictability in their revenue, while also providing the potential for upside from new launches and cross-sell opportunities. With a more conservative posture towards reserves and a two-year pathway to normalized margins, the company is set up for outsized growth in the coming years.

Bears say

Evolent Health is facing several challenges that could impact its financial performance and growth, including regulatory uncertainty, macroeconomic headwinds, and renegotiations of existing contracts. The company's dependence on oncology care management also introduces risks, as rising cancer rates could strain its effectiveness in containing costs. Additionally, Evolent's efforts to reduce costs and consolidate administrative services may provide some mitigation, but they could also result in execution risks and potential revenue pressures. Overall, these factors lead to a negative outlook on the company's stock due to the uncertainty and potential impact on its financials.

Evolent Health (EVH) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 14 analysts, Evolent Health (EVH) has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.